In:
Medicine, Ovid Technologies (Wolters Kluwer Health), Vol. 98, No. 32 ( 2019-08), p. e16592-
Kurzfassung:
Refractory nasopharyngeal carcinoma is challenging to treat and at present there is no standard treatment or any good choice. Patient concerns: Although the three patients in our case reports had already underwent multiple treatments before, they still suffered from disease recurrence of nasopharyngeal carcinoma. Diagnosis: They were diagnosed as refractory nasopharyngeal carcinoma. Interventions: A continuous infusion of Endostar, an antiangiogenic agent, combined with chemotherapy and radiation therapy was given to treat the patients. Outcomes: Patients showed complete or partial response to the combined therapy as evidenced by regression of tumors and decrease in plasma Epstein–Barr virus (EBV) DNA load. Lessons: Continuous infusions of Endostar in combination with chemotherapy and/or radiation therapy showed promising efficacy and safety. The combination therapy indicates a new approach to treat refractory nasopharyngeal carcinoma.
Materialart:
Online-Ressource
ISSN:
0025-7974
,
1536-5964
DOI:
10.1097/MD.0000000000016592
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2019
ZDB Id:
2049818-4